Stonepine Capital Management, LLC An2 Therapeutics, Inc. Transaction History
Stonepine Capital Management, LLC
- $124 Billion
- Q4 2024
A detailed history of Stonepine Capital Management, LLC transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Stonepine Capital Management, LLC holds 196,732 shares of ANTX stock, worth $224,274. This represents 0.22% of its overall portfolio holdings.
Number of Shares
196,732Holding current value
$224,274% of portfolio
0.22%Shares
1 transactions
Others Institutions Holding ANTX
# of Institutions
38Shares Held
13.8MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$6.55 Million4.93% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.31MShares$1.5 Million0.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.18 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny580KShares$660,9410.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY579KShares$659,8600.79% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $22.1M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...